Immuneering Corporation
12:00 PM - 12:15 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 103
Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, our universal-MAPK inhibitor, as well as several early-stage programs.
Ticker:
$IMRX
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Oncology
Lead Product in Development:
IMM-1-104
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2 or more
Speaker
